Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Myokardia Inc    MYOK

MYOKARDIA INC (MYOK)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/17/2018 01/18/2018 01/19/2018 01/22/2018 01/23/2018 Date
52.6(c) 52.9(c) 53.95(c) 54(c) 55.2 Last
344 933 243 746 640 192 417 390 427 103 Volume
+1.15% +0.57% +1.98% +0.09% +2.22% Change
More quotes
Financials ($)
Sales 2017 23,0 M
EBIT 2017 -33,0 M
Net income 2017 -54,3 M
Finance 2017 228 M
Yield 2017 -
Sales 2018 25,3 M
EBIT 2018 -49,3 M
Net income 2018 -79,2 M
Finance 2018 230 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 74,1x
EV / Sales2018 67,1x
Capitalization 1 930 M
More Financials
Company
MyoKardia, Inc. is a biopharmaceutical company.It engages in the discovery, development, and commercialization of targeted therapies for the treatment of cardiovascular diseases.The company focuses on the treatment of heritable cardiomyopathies, genetically-driven forms of heart failure that result... 
More about the company
Surperformance© ratings of Myokardia Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on MYOKARDIA INC
01/22 BIOCENTURY - MANAGEMENT TRACKS : Shire, Sosei
01/20 MYOKARDIA : Announces Appointment of Cynthia Ladd as General Counsel
01/19 MyoKardia Announces Appointment of Cynthia Ladd as General Counsel
01/03 MyoKardia to Present at 36th Annual J.P. Morgan Healthcare Conference
2017 SANOFI : faces a make-or-break year, saying its ready to put a 3-prong R&D strat..
2017 MYOKARDIA : Preclinical Studies with MyoKardia's Mavacamten Demonstrate Evidence..
2017 MYOKARDIA : Presents Data from Study of Machine Learning Algorithm Intended to I..
2017 MYOKARDIA : Presents Data from Study of Machine Learning Algorithm Intended to I..
2017 MYOKARDIA : Preclinical Studies with MyoKardia’s Mavacamten Demonstrate Ev..
2017 MyoKardia Presents Data from Study of Machine Learning Algorithm Intended to ..
More news
Sector news : Bio Therapeutic Drugs
08:48a Drug Firms Bet Billions on Biotech -- WSJ
01/22 Stocks hit record as senators reach deal to end shutdown
01/22 Big Drugmakers Pay Big Prices for Promising Biotechs
01/22 Dealmaking drives European stocks as equity melt-up continues
01/22 Biotech M&A takes off as Sanofi and Celgene spend $20 billion
More sector news : Bio Therapeutic Drugs
Latest Tweets
01/19Up and Down the Ladder: Job Changes.. the latest comings and goings.. recogni.. 
01/19MyoKardia Announces Appointment of Cynthia Ladd as General Counsel  
01/18+Initiations 1/18: $ALXN $ARNA $AVXS $AVY $BMRN $CAT $COP $EA $EDGE $ESPR $HE..
2
01/18Head-To-Head Analysis: Aurinia Pharmaceuticals $AUPH vs. Myokardia $MYOK  
01/15Myokardia $MYOK Receiving Somewhat Favorable Media Coverage, Analysis Finds  
More tweets
Qtime:143
News from SeekingAlpha
01/19 ROTY EDITION 1 VOLUME 71 : Thoughts On A Juno Buyout, Outperformance Continues A..
01/12 YOUR DAILY PHARMA SCOOP : AbbVie Highlights Pipeline, Novavax Surges, Lipocine F..
01/12 4 Small-Cap Biotechs With Near-Term Trading Catalysts
01/09 YOUR DAILY PHARMA SCOOP : Ablynx Takeover Bid, Celgene Acquires Impact Biomedici..
01/05 YOUR DAILY PHARMA SCOOP : ChemoCentryx Surges, Akebia Gets Positive News, Atara ..
Chart MYOKARDIA INC
Duration : Period :
Myokardia Inc Technical Analysis Chart | MYOK | US62857M1053 | 4-Traders
Technical analysis trends MYOKARDIA INC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 57,0 $
Spread / Average Target 5,6%
EPS Revisions
Managers
NameTitle
Anastasios E. Gianakakos President, Chief Executive Officer & Director
June Lee Chief Operating Officer
Jake Bauer Chief Financial Officer
Marc Semigran Chief Medical Officer
Michael P. Graziano Vice President-Research Biology
Sector and Competitors
1st jan.Capitalization (M$)
MYOKARDIA INC28.27%1 930
GILEAD SCIENCES13.04%106 315
VERTEX PHARMACEUTICALS5.41%40 948
REGENERON PHARMACEUTICALS-1.18%40 382
GENMAB13.75%11 797
BIOVERATIV INC18.90%11 230